
Cerveau Technologies has signed an agreement to provide Roche with the PET radiotracer F-18 MK-6240 for assessing the status and progression of tau neurofibrillary tangles (NFTs) in the brain.
Tau protein NFTs are a hallmark of several neurodegenerative diseases, including Alzheimer's disease. F-18 MK-6240 was developed to measure tau levels of PET scans. Roche will use the investigational tracer to help develop potential therapeutic treatments.












![Comparative PET/CT scan images showing [18F]FAPI and [18F]FDG imaging with MIP projections, fusion views, and CT cross-sections for medical diagnosis](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/10/fapi-vs-fdg.nL6Acp6W2i.jpg?auto=format%2Ccompress&fit=crop&h=112&q=70&w=112)





